New drug targets rare BRAF mutations in advanced cancers
NCT ID NCT06400225
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 28 times
Summary
This study tests a drug called ulixertinib in 35 adults with advanced cancers that have certain BRAF gene changes (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. The main goal is to see how many patients' tumors shrink or disappear. This is a phase 2 trial for people whose cancer has not responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.